All patients
Age < 65y (younger) Age > 65y Gender, female Gender, male PDL1 (CPS < 1) PDL1 (CPS >1) Risk favorable (IMDC) Risk favorable (MSKCC) Risk intermediate (IMDC) Risk intermediate (MSKCC) Risk poor (IMDC) Risk poor (MSKCC)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced RCC (mRCC) - 1st line (L1), pembrolizumab plus lenvatinib vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-581/CLEAR (PDL1), 2021 0.66 [0.49; 0.88]
0.66 [0.49 ; 0.88 ] KEYNOTE-581/CLEAR (PDL1), 2021 1 0% 712 NA not evaluable progression or deaths (PFS)detailed results KEYNOTE-581/CLEAR (PDL1), 2021 0.39 [0.32; 0.48]
0.39 [0.32 ; 0.48 ] KEYNOTE-581/CLEAR (PDL1), 2021 1 0% 712 NA not evaluable objective responses (ORR)detailed results KEYNOTE-581/CLEAR (PDL1), 2021 1.97 [1.69; 2.29]
1.97 [1.69 ; 2.29 ] KEYNOTE-581/CLEAR (PDL1), 2021 1 0% 712 NA not evaluable AE (any grade)detailed results Out of scale KEYNOTE-581/CLEAR (PDL1), 2021 NaN [NaN; NaN]
NaN [NaN ; NaN ] KEYNOTE-581/CLEAR (PDL1), 2021 1 0% 592 NA not evaluable AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (PDL1), 2021 0.11 [0.05; 0.24]
0.11 [0.05 ; 0.24 ] KEYNOTE-581/CLEAR (PDL1), 2021 1 0% 592 NA not evaluable AE leading to death (grade 5)detailed results KEYNOTE-581/CLEAR (PDL1), 2021 0.93 [0.42; 2.05]
0.93 [0.42 ; 2.05 ] KEYNOTE-581/CLEAR (PDL1), 2021 1 0% 592 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results KEYNOTE-581/CLEAR (PDL1), 2021 2.31 [1.58; 3.38]
2.31 [1.58 ; 3.38 ] KEYNOTE-581/CLEAR (PDL1), 2021 1 0% 592 NA not evaluable Arthralgia AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (PDL1), 2021 4.88 [0.57; 42.03]
4.88 [0.57 ; 42.03 ] KEYNOTE-581/CLEAR (PDL1), 2021 1 0% 692 NA not evaluable Constipation AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (PDL1), 2021 5.84 [0.29; 116.96]
5.84 [0.29 ; 116.96 ] KEYNOTE-581/CLEAR (PDL1), 2021 1 0% 692 NA not evaluable Decreased appetite AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (PDL1), 2021 2.78 [0.99; 7.79]
2.78 [0.99 ; 7.79 ] KEYNOTE-581/CLEAR (PDL1), 2021 1 0% 692 NA not evaluable Diarrhoea AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (PDL1), 2021 1.91 [1.06; 3.46]
1.91 [1.06 ; 3.46 ] KEYNOTE-581/CLEAR (PDL1), 2021 1 0% 692 NA not evaluable Dysgeusia AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (PDL1), 2021 0.97 [0.06; 15.50]
0.97 [0.06 ; 15.50 ] KEYNOTE-581/CLEAR (PDL1), 2021 1 0% 692 NA not evaluable Dysphonia AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (PDL1), 2021 0.97 [0.02; 48.82]
0.97 [0.02 ; 48.82 ] KEYNOTE-581/CLEAR (PDL1), 2021 1 0% 692 NA not evaluable Fatigue AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (PDL1), 2021 0.96 [0.46; 2.00]
0.96 [0.46 ; 2.00 ] KEYNOTE-581/CLEAR (PDL1), 2021 1 0% 692 NA not evaluable Hypertension AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (PDL1), 2021 1.64 [1.15; 2.35]
1.64 [1.15 ; 2.35 ] KEYNOTE-581/CLEAR (PDL1), 2021 1 0% 692 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (PDL1), 2021 9.78 [0.53; 179.78]
9.78 [0.53 ; 179.78 ] KEYNOTE-581/CLEAR (PDL1), 2021 1 0% 692 NA not evaluable Nausea AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (PDL1), 2021 4.43 [0.95; 20.68]
4.43 [0.95 ; 20.68 ] KEYNOTE-581/CLEAR (PDL1), 2021 1 0% 692 NA not evaluable Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (PDL1), 2021 1.04 [0.48; 2.25]
1.04 [0.48 ; 2.25 ] KEYNOTE-581/CLEAR (PDL1), 2021 1 0% 692 NA not evaluable Proteinuria AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (PDL1), 2021 2.74 [1.31; 5.76]
2.74 [1.31 ; 5.76 ] KEYNOTE-581/CLEAR (PDL1), 2021 1 0% 692 NA not evaluable Rash AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (PDL1), 2021 6.48 [1.45; 28.94]
6.48 [1.45 ; 28.94 ] KEYNOTE-581/CLEAR (PDL1), 2021 1 0% 692 NA not evaluable Stomatitis AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (PDL1), 2021 0.82 [0.27; 2.48]
0.82 [0.27 ; 2.48 ] KEYNOTE-581/CLEAR (PDL1), 2021 1 0% 692 NA not evaluable Vomiting AE (grade 3-4)detailed results KEYNOTE-581/CLEAR (PDL1), 2021 2.36 [0.82; 6.79]
2.36 [0.82 ; 6.79 ] KEYNOTE-581/CLEAR (PDL1), 2021 1 0% 692 NA not evaluable Weight decreased AE (grade 3-4)detailed results Out of scale KEYNOTE-581/CLEAR (PDL1), 2021 29.30 [3.96; 216.58]
29.30 [3.96 ; 216.58 ] KEYNOTE-581/CLEAR (PDL1), 2021 1 0% 692 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-06 15:04 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 79,178,152
- treatments: 767